Guiu S, Balmana J, Lemercier P, Follana P, et al. Combination of olaparib, durvalumab and fulvestrant in patients with advanced ER+/HER2- breast cancer and selected genomic alterations: results of the DOLAF trial. Clin Cancer Res 2025 Sep 23. doi: 10.1158/1078-0432.CCR-24-4221.
PMID: 40986529